Preserving the Sanctity of Overall Survival for Drugs Approved on the Basis of Progression-Free Survival: Tivozanib As a Case Study
Mené sur 517 patients atteints d'un carcinome métastatique à cellules rénales, cet essai de phase III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité du tivozanib et du sorafenib en traitement de première ligne
For decades, physicians had a paucity of active agents for treating patients with advanced or metastatic renal cell cancer (RCC). It would have been unimaginable for those physicians practicing medicine in the 1980s and 1990s that the new millennium would see the approval of seven agents that could significantly benefit patients in this difficult disease setting...
Journal of Clinical Oncology , éditorial en libre accès, 2013